Skip to main content

Peer Review reports

From: First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes

Original Submission
17 Jan 2022 Submitted Original manuscript
20 Jan 2022 Reviewed Reviewer Report
30 Jan 2022 Reviewed Reviewer Report
4 Feb 2022 Reviewed Reviewer Report
6 Feb 2022 Reviewed Reviewer Report
7 Feb 2022 Reviewed Reviewer Report
20 Feb 2023 Author responded Author comments - Jean van Rampelbergh
Resubmission - Version 2
20 Feb 2023 Submitted Manuscript version 2
23 Feb 2023 Reviewed Reviewer Report
7 Mar 2023 Reviewed Reviewer Report
9 Mar 2023 Reviewed Reviewer Report
12 Apr 2023 Author responded Author comments - Jean van Rampelbergh
Resubmission - Version 3
12 Apr 2023 Submitted Manuscript version 3
18 Apr 2023 Reviewed Reviewer Report
9 May 2023 Author responded Author comments - Jean van Rampelbergh
Resubmission - Version 4
9 May 2023 Submitted Manuscript version 4
Publishing
10 May 2023 Editorially accepted
24 May 2023 Article published 10.1186/s12916-023-02900-z

You can find further information about peer review here.

Back to article page